Genmab A/S (GMAB) News Today → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free GMAB Stock Alerts $29.29 +0.26 (+0.90%) (As of 05/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCapital Increase in Genmab as a Result of Employee Warrant Exerciseglobenewswire.com - May 7 at 2:27 PMGenmab A/S (NASDAQ:GMAB) Shares Gap Up to $27.72americanbankingnews.com - May 5 at 2:46 AMOptimistic Outlook for Genmab: Strategic Growth and Product Performance Underpin Buy Ratingmarkets.businessinsider.com - May 3 at 6:02 PMGenmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - May 3 at 1:01 PMGenmab A/S 2024 Q1 - Results - Earnings Call Presentationseekingalpha.com - May 2 at 12:38 PMGenmab Announces Financial Results for the First Quarter of 2024globenewswire.com - May 2 at 11:01 AMShort Interest in Genmab A/S (NASDAQ:GMAB) Expands By 9.6%americanbankingnews.com - May 2 at 1:58 AMGenmab: A Complicated Taleseekingalpha.com - May 1 at 10:27 AMGenmab A/S's (GMAB) "Buy" Rating Reaffirmed at HC Wainwrightamericanbankingnews.com - May 1 at 3:26 AMShort Interest in Genmab A/S (NASDAQ:GMAB) Grows By 9.6%marketbeat.com - April 30 at 9:35 AMHC Wainwright Reaffirms Buy Rating for Genmab A/S (NASDAQ:GMAB)marketbeat.com - April 30 at 8:35 AMPfizer, Genmab cervical cancer therapy wins full FDA approvalmsn.com - April 30 at 8:10 AMFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancerbusinesswire.com - April 29 at 6:40 PMTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancerbusinesswire.com - April 29 at 6:40 PMTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancerglobenewswire.com - April 29 at 6:40 PMTransactions in Connection with Share Buy-back Program Genmabglobenewswire.com - April 29 at 4:24 AMTransactions in Connection with Share Buy-back Program Genmabglobenewswire.com - April 22 at 3:30 AMGenmab A/S (GMAB)finance.yahoo.com - April 20 at 10:45 PMCerity Partners LLC Acquires 42,661 Shares of Genmab A/S (NASDAQ:GMAB)marketbeat.com - April 20 at 5:32 AMGenmab A/S (NASDAQ:GMAB) to Post FY2024 Earnings of $0.88 Per Share, William Blair Forecastsmarketbeat.com - April 19 at 8:51 AMGenmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.43marketbeat.com - April 17 at 11:37 AMGenmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2024finanznachrichten.de - April 16 at 8:05 AMGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024globenewswire.com - April 16 at 6:24 AMTransactions in Connection with Share Buy-back Program Genmabglobenewswire.com - April 15 at 4:07 AMShort Interest in Genmab A/S (NASDAQ:GMAB) Increases By 17.1%marketbeat.com - April 14 at 7:21 PMGenmab A/S (NASDAQ:GMAB) Shares Acquired by NewEdge Wealth LLCmarketbeat.com - April 14 at 6:57 AMGenmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Hold" by Brokeragesmarketbeat.com - April 14 at 2:27 AMGenmab A/S (NASDAQ:GMAB) Stake Trimmed by Hardman Johnston Global Advisors LLCmarketbeat.com - April 12 at 9:38 PMTransactions in Connection with Share Buy-back Programglobenewswire.com - April 8 at 5:44 AMBrokers Offer Predictions for Genmab A/S's FY2025 Earnings (NASDAQ:GMAB)marketbeat.com - April 8 at 2:33 AM185,698 Shares in Genmab A/S (NASDAQ:GMAB) Acquired by ANTIPODES PARTNERS Ltdmarketbeat.com - April 5 at 4:53 PMGenmab A/S (NASDAQ:GMAB) Expected to Earn Q2 2024 Earnings of $0.28 Per Sharemarketbeat.com - April 5 at 8:22 AMGenmab Stock (NASDAQ:GMAB), Quotes and News Summarybenzinga.com - April 5 at 8:08 AMGenmab A/S (NASDAQ:GMAB) Shares Gap Up to $29.30marketbeat.com - April 4 at 1:20 PMGenmab Buys Ovarian Cancer Drug Developer for $1.8 Billionmsn.com - April 3 at 7:18 PMProfoundBio to be acquired by Danish biotech giant Genmab for $1.8 billionbizjournals.com - April 3 at 7:18 PMGenmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.96marketbeat.com - April 3 at 2:54 PMM&A News: Genmab (NASDAQ:GMAB) Is Acquiring ProfoundBio for $1.8Bmsn.com - April 3 at 2:18 PMGenmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeoverfinance.yahoo.com - April 3 at 2:18 PMGenmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolioinvestopedia.com - April 3 at 9:20 AMGenmab to purchase US-based biotech company ProfoundBio for $1.8 billion in all-cash dealmsn.com - April 3 at 9:18 AMGenmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBiofinance.yahoo.com - April 3 at 9:18 AMDenmark's Genmab to acquire ProfoundBio for $1.8 billionreuters.com - April 3 at 3:47 AMGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBiobusinesswire.com - April 3 at 1:35 AMGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioglobenewswire.com - April 3 at 1:34 AMShort Interest in Genmab A/S (NASDAQ:GMAB) Grows By 10.2%marketbeat.com - April 2 at 10:00 AMTransactions in Connection with Share Buy-back Programglobenewswire.com - April 2 at 3:24 AMGenmab A/S (NASDAQ:GMAB) Receives Buy Rating from HC Wainwrightmarketbeat.com - March 27 at 8:18 AMGenmab A/S (NASDAQ:GMAB) Shares Gap Up to $29.98marketbeat.com - March 26 at 12:26 PMMorgan Stanley Reaffirms Underweight Rating for Genmab A/S (NASDAQ:GMAB)marketbeat.com - March 26 at 12:01 PM Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address The Department of Defense Has a New Drone Contractor (Ad)The Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes. Click here to see how to invest GMAB Media Mentions By Week GMAB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼0.640.38▲Average Medical News Sentiment GMAB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼114▲GMAB Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alnylam Pharmaceuticals News Today Teva Pharmaceutical Industries News Today BioMarin Pharmaceutical News Today BeiGene News Today Viatris News Today Karuna Therapeutics News Today Dr. Reddy's Laboratories News Today Sarepta Therapeutics News Today United Therapeutics News Today Catalent News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
